0000899243-21-032389.txt : 20210810 0000899243-21-032389.hdr.sgml : 20210810 20210810181956 ACCESSION NUMBER: 0000899243-21-032389 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210806 FILED AS OF DATE: 20210810 DATE AS OF CHANGE: 20210810 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Ray Nitya G. CENTRAL INDEX KEY: 0001709522 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-49908 FILM NUMBER: 211161380 MAIL ADDRESS: STREET 1: 14 BAYBURY COURT CITY: EAST HANOVER STATE: NJ ZIP: 07936 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: CytoDyn Inc. CENTRAL INDEX KEY: 0001175680 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 753056237 STATE OF INCORPORATION: DE FISCAL YEAR END: 0531 BUSINESS ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 BUSINESS PHONE: 360-980-8524 MAIL ADDRESS: STREET 1: 1111 MAIN STREET, SUITE 660 CITY: VANCOUVER STATE: WA ZIP: 98660 FORMER COMPANY: FORMER CONFORMED NAME: CYTODYN INC DATE OF NAME CHANGE: 20031114 FORMER COMPANY: FORMER CONFORMED NAME: REXRAY CORP DATE OF NAME CHANGE: 20020617 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-08-06 1 0001175680 CytoDyn Inc. CYDY 0001709522 Ray Nitya G. 1111 MAIN STREET, SUITE 660 VANCOUVER WA 98660 0 1 0 0 Chief Technology Officer Common stock 2021-08-06 4 A 0 34801 0.00 A 234801 D Common stock 2021-08-06 4 A 0 52500 0.00 A 287301 D Non-qualified stock option (right to buy) 1.32 2021-08-06 4 A 0 500000 0.00 A 2031-08-06 Common stock 500000 500000 D Represents shares received in lieu of 50% of a cash incentive bonus paid for services performed during the fiscal year ended May 31, 2021, which may be paid (a) 100% in cash or (b) 50% in stock and 50% in cash, as determined by the issuer's compensation committee of the board of directors. Represents shares received in satisfaction of performance share award based on the achievement of specified performance goals for the fiscal year ended May 31, 2021, as determined by the issuer's compensation committee of the board of directors. The option vests in three equal annual installments beginning on August 6, 2022. /s/ Antonio Migliarese Attorney-in-fact 2021-08-10